Orchestra BioMed (NASDAQ:OBIO) Insider David Hochman Purchases 5,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $3.77 per share, for a total transaction of $18,850.00. Following the acquisition, the insider owned 1,059,029 shares of the company’s stock, valued at $3,992,539.33. This represents a 0.47% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Orchestra BioMed Trading Up 7.0%

Shares of Orchestra BioMed stock opened at $3.98 on Tuesday. The company has a 50-day moving average of $4.28 and a two-hundred day moving average of $4.27. Orchestra BioMed Holdings, Inc. has a 12-month low of $2.20 and a 12-month high of $5.42. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The stock has a market cap of $238.32 million, a PE ratio of -4.10 and a beta of 0.52.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.07. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. On average, research analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.62 EPS for the current fiscal year.

Key Orchestra BioMed News

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 each, a $82,600 purchase that increased his stake by 27.89%. Insider buying can signal management confidence in the company’s outlook. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while raising several earnings estimates for 2026 and 2027. The higher forecast for Q2 2026 EPS and improved longer-term projections suggest analysts see somewhat better fundamentals ahead. Article Title
• Neutral Sentiment: HC Wainwright’s updated estimates still show losses for every quarter and year covered, so the company remains unprofitable in the near term despite the upgrades. Article Title
• Neutral Sentiment: Recent analyst commentary remains mixed overall, with some firms maintaining bullish ratings while others have downgraded the stock, keeping sentiment somewhat split. Article Title

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings lowered Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, March 12th. Barclays raised their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OBIO. China Universal Asset Management Co. Ltd. purchased a new position in Orchestra BioMed in the 4th quarter valued at about $38,000. Creative Planning purchased a new stake in shares of Orchestra BioMed during the second quarter worth about $40,000. XTX Topco Ltd purchased a new stake in shares of Orchestra BioMed during the second quarter worth about $45,000. Jane Street Group LLC acquired a new position in shares of Orchestra BioMed in the second quarter valued at approximately $50,000. Finally, Virtu Financial LLC purchased a new position in shares of Orchestra BioMed during the fourth quarter valued at approximately $57,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.